Scientific article
English

Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome

Published in

American journal of physiology: endocrinology and metabolism, vol. 300, no. 4, p. E681-690

Publication date

2011

Abstract

Metabolic syndrome is a proatherosclerotic condition clustering cardiovascular risk factors, including glucose and lipid profile alterations. The pathophysiological mechanisms favoring atherosclerotic inflammation in the metabolic syndrome remain elusive. Here, we investigated the potential role of the antilipolytic drug acipimox on neutrophil- and monocyte-mediated inflammation in the metabolic syndrome. Acipimox (500 mg) was orally administered to metabolic syndrome patients (n = 11) or healthy controls (n = 8). Serum and plasma was collected before acipimox administration (time 0) as well as 2-5 h afterward to assess metabolic and hematologic parameters. In vitro, the effects of the incubation with metabolic syndrome serum were assessed on human neutrophil and monocyte migration toward the proatherosclerotic chemokine CCL3. Two to five hours after acipimox administration, a significant reduction in circulating levels of insulin and nonesterified fatty acid (NEFA) was shown in metabolic syndrome patients. At time 0 and 2 h after acipimox administration, metabolic syndrome serum increased neutrophil migration to CCL3 compared with healthy controls. No effect was shown in human monocytes. At these time points, serum-induced neutrophil migration positively correlated with serum levels of insulin and NEFA. Metabolic syndrome serum or recombinant insulin did not upregulate CCR5 expression on neutrophil surface membrane, but it increased intracellular JNK1/2 phosphorylation. Insulin immunodepletion blocked serum-induced neutrophil migration and associated JNK1/2 phosphorylation. Although mRNA expression of acipimox receptor (GPR109) was shown in human neutrophils, 5-500 μM acipimox did not affect insulin-induced neutrophil migration. In conclusion, results suggest that acipimox inhibited neutrophil proatherosclerotic functions in the metabolic syndrome through the reduction in circulating levels of insulin.

Keywords

  • Administration, Oral
  • Adult
  • Algorithms
  • Cells, Cultured
  • Down-Regulation/drug effects
  • Female
  • Humans
  • Hypolipidemic Agents/administration & dosage/pharmacology
  • Inflammation/blood/complications/immunology/prevention & control
  • Insulin/blood/metabolism
  • Male
  • Metabolic Syndrome X/blood/complications/drug therapy/immunology
  • Middle Aged
  • Neutrophils/immunology/physiology
  • Pyrazines/administration & dosage/pharmacology
  • Time Factors

Citation (ISO format)

MONTECUCCO, Fabrizio et al. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. In: American journal of physiology: endocrinology and metabolism, 2011, vol. 300, n° 4, p. E681–690. doi: 10.1152/ajpendo.00527.2010

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

0193-1849
682views
0downloads

Technical informations

Creation

09/02/2016 15:30:00

First validation

09/02/2016 15:30:00

Update

23/01/2025 11:33:47

Status update

23/01/2025 11:33:47

Last indexation

23/01/2025 11:41:41
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated